Inovio Pharmaceuticals Inc. reported positive preliminary results from the first-phase trial of its vaccine candidate for the new coronavirus, citing good indications for the vaccine’s safety and potential to protect against the virus in a small initial study. The drugmaker said the vaccine candidate, which it calls INO-4800, was well-tolerated by participants during an eight-week span, and that 34 of 36 participants demonstrated overall immune responses six weeks into taking two doses.

Source: Wall Street Journal June 30, 2020 16:52 UTC